Key Catalyst for US Biopharma Stock on Track for Q4/23

Research Report
  ()
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report.

Medical Device Co. Completes Merger in Q1/23

Research Report
  ()
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report.

FDA Approval, Private Placement Funding Buoy Biotech Firm

  ()
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement.

Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23

Research Report
  ()
This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report.

Telehealth Co. Notches First Profitable Quarter

  ()
Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022.

Stock of Canadian Health Tech Firm Upgraded To Good

Research Report
  ()
Since the previous rating, this firm has experienced improvements in its business market sentiment and technicals, noted a SADIF Investment Analytics report.

Analyst Says Pharma Co. 'Meaningfully Undervalued'

Research Report
  ()
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.

U.S. Firm's Earnings To Remain Robust Through 2023

Research Report
  ()
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report.
Tags:  Cannabis

Animal Feed Company Evaluating Strategic Alternatives

  ()
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit.

Wellness Co.'s Q1/23 Results Better Than Expected

Research Report
  ()
Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note.
Tags:  Cannabis

Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients

  ()
Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients.

Biopharma Co. Ceases Program to Optimize Resources

Research Report
  ()
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report.

Digital Health Co. Grows Revenue and Reduces Expenses

Research Report
  ()
This Canadian healthcare tech company is showing projected returns of over 241% for investors, noted an Echelon Capital Markets research note.

Telehealth Co. Expands into Arkansas

  ()
Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform, including its first contract in the state of Arkansas, where chronic diseases cost billions annually.

Pharmaceutical Company Sets Gold Standard for New Drugs

  ()
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.

Adding Silver a Solid Move

Contributed Opinion
  ()
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market.

Expert Investing Ideas

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation


"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

As Countries Bolster Defense, Opportunities Emerge

  ()
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability.

Blockchain Co., Vets Group Team Up for App

  ()
A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets.

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial

  ()
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill.

Co.'s New Cell Therapy Shows Positive Effects

Research Report
  ()
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report.

Biotech Rated Outperform Advances Top Drug Candidate

Research Report
  ()
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report.